<DOC>
	<DOCNO>NCT00444184</DOCNO>
	<brief_summary>This 8-week , crossover study compare quality 24-hour IOP control TTFC versus travoprost medication dose even . Such crossover comparison may determine real efficacy new fix combination versus travoprost monotherapy . The result enhance investigator understand best dose TTFC may influence clinical use Europe . Finally , result would better delineate future role TTFC glaucoma management PG monotherapy , instead unfixed therapy PG analog timolol . This study assist general ophthalmologist worldwide plan optimal stepwise medical therapy .</brief_summary>
	<brief_title>24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Consecutive adult primary openangle glaucoma ( POAG ) exhibit mean untreated IOP great 23 Hg baseline ( 10:00 ) . Patient POAG old 29 year The IOP without treatment great 23 mm Hg low 38 mm Hg baseline ( 2 reading 10:00 ) Patient safely wash without risk significant deterioration Distance best correct Snellen visual acuity well 1/10 Patient understand instruction comply medication Open normal appear angle Contraindications prostaglandins Î²blockers History lack response ( &lt; 10 % reduction ) medication Female childbearing potential lactating mother History trauma , inflammation , surgery , past use steroid ( within 2 month ) , severe dry eye use contact lens Sign ocular infection , except blepharitis , corneal abnormality may affect IOP measurement etc</criteria>
	<gender>All</gender>
	<minimum_age>29 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>travoprost/timolol fix combination</keyword>
</DOC>